Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Florida
MedSIR
Royal Marsden NHS Foundation Trust
Dana-Farber Cancer Institute
University of Florida
Essen Biotech